BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the submission of a Marketing Authorization Application to the European Medicines Agency for vosoritide, an investigational, once-daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.Novavax, Inc. (NASDAQ: NVAX) said it will release the Phase 1 data, which will consist of preliminary immunogenicity and safety results, during the first week of August, as opposed to the earlier timeframe of July.